Equities

Unicycive Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
UNCY:NAQ

Unicycive Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)6.22
  • Today's Change0.02 / 0.32%
  • Shares traded348.82k
  • 1 Year change+5.05%
  • Beta1.8319
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.

  • Revenue in USD (TTM)0.00
  • Net income in USD-33.47m
  • Incorporated2016
  • Employees22.00
  • Location
    Unicycive Therapeutics Inc4300 El Camino Real, Suite 210LOS ALTOS 94022United StatesUSA
  • Phone+1 (650) 384-0642
  • Fax+1 (302) 655-5049
  • Websitehttps://unicycive.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Black Diamond Therapeutics Inc70.00m21.50m126.48m24.006.121.005.791.810.36290.36291.232.220.4736----2,916,667.0014.54-42.2416.58-46.05----30.71------0.00------15.48------
AVITA Medical Inc72.40m-48.56m127.43m260.00------1.76-1.81-1.812.70-0.21861.001.637.50278,461.50-67.07---147.57--84.81---67.06--0.5519-8.201.19--28.14---74.80------
Oramed Pharmaceuticals, Inc.2.00m43.85m129.36m13.003.230.65292.9464.681.011.010.04784.980.0104----153,846.2022.72--23.30--0.65--2,190.40------0.00---100.00---444.98------
Corbus Pharmaceuticals Holdings Inc0.00-67.51m132.70m28.00--1.03-----5.51-5.510.007.350.00----0.00-49.34-69.78-55.11-97.84-------5,894.85----0.00------9.85------
Unicycive Therapeutics Inc0.00-33.47m133.25m22.00--3.45-----2.85-2.850.001.800.00----0.00-74.93-188.44-101.88-723.53-------6,003.20----0.00---100.00---20.42------
vTv Therapeutics Inc17.00k-23.47m133.39m23.00--1.89--7,846.40-3.32-3.320.002417.910.0002----739.13-39.79-96.30-46.08-------166,935.30-775.06----0.0046-----18.128.83------
Spero Therapeutics Inc40.55m-43.84m134.65m32.00--5.08--3.32-0.7949-0.79490.72990.47050.4283--1.451,267,156.00-46.31-35.16-69.26-42.63-----108.11-111.75----0.00---53.7721.46-400.65------
Vaxart Inc148.20m-50.70m135.88m105.00--4.84--0.9168-0.2222-0.22220.64950.11690.789--3.311,411,467.00-26.99-49.90-80.48-58.33-----34.21-875.06---31.430.1161--288.9423.8218.82---8.21--
Sangamo Therapeutics Inc32.88m-108.91m138.20m183.00--19.96--4.20-0.4428-0.44280.13260.01940.3289--5.97179,644.80-108.96-30.73-204.29-37.33-----331.28-147.59----0.00---67.20-10.8162.01---58.10--
HST Global Inc0.00-212.63k139.70m1.00--8.48-----0.0107-0.01070.000.11670.00-------6.87-27.80-8.09-60.19-----------107.480.0433-------45.42------
Nkarta Inc0.00-102.61m139.93m105.00--0.4141-----1.39-1.390.004.760.00----0.00-21.39-29.78-22.36-31.23------------0.00------7.41--17.99--
Prelude Therapeutics Inc10.50m-111.77m140.19m131.00--2.16--13.35-1.47-1.470.13821.030.0719----80,152.67-76.56-47.36-88.86-51.44-----1,064.50-7,615.23----0.00-------4.38---0.4137--
Tenaya Therapeutics Inc0.00-94.26m141.07m97.00--1.30-----0.7875-0.78750.000.50610.00----0.00-76.77-47.44-87.21-51.82------------0.00------10.44---18.92--
Fate Therapeutics Inc7.14m-156.09m144.19m181.00--0.616--20.20-1.32-1.320.06032.030.017--2.3039,430.94-37.23-32.44-40.38-36.57-----2,187.11-389.06----0.00---78.555.00-15.74---37.07--
Milestone Pharmaceuticals Inc0.00-58.01m144.79m33.00--7.06-----0.8938-0.89380.000.24070.00----0.00-68.07-48.63-75.01-52.10-------1,201.96---73.280.7327---100.00--30.44---39.67--
Connect Biopharma Holdings Ltd (ADR)762.00k-50.77m145.35m62.00--2.62--190.75-0.9144-0.91440.01370.9926------12,290.32---61.12---66.78-----6,662.99-1,963.00----0.00------74.84--37.04--
Data as of Feb 17 2026. Currency figures normalised to Unicycive Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

25.65%Per cent of shares held by top holders
HolderShares% Held
Millennium Management LLCas of 16 Jan 20261.17m5.46%
Octagon Capital Advisors LPas of 31 Dec 20251.00m4.65%
Nantahala Capital Management LLCas of 31 Dec 2025939.20k4.37%
Great Point Partners LLCas of 30 Sep 2025796.56k3.71%
The Vanguard Group, Inc.as of 31 Dec 2025679.65k3.16%
Logos Global Management LPas of 30 Sep 2025473.56k2.20%
Geode Capital Management LLCas of 31 Dec 2025171.29k0.80%
Vanguard Fiduciary Trust Co.as of 31 Dec 2025101.07k0.47%
BNP Paribas Financial Marketsas of 31 Dec 202599.74k0.46%
OMERS Administration Corp.as of 31 Dec 202578.20k0.36%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.